<DOC>
	<DOCNO>NCT00762645</DOCNO>
	<brief_summary>The purpose study demonstrate Intraocular Pressure ( IOP ) lower efficacy Travoprost Ophthalmic Solution 0.004 % superior Pilocarpine 1 % patient chronic angle-closure glaucoma ( CACG ) .</brief_summary>
	<brief_title>Travoprost 0.004 % Versus Pilocarpine 1 % Patients With Chronic Angle Closure Glaucoma ( CACG )</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Angle-Closure</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Pilocarpine</mesh_term>
	<criteria>Age ≥ 18 year Chronic Angle Closure Glaucoma ( CACG ) 2135 millimeter mercury mean intraocular pressure Eligibility visit day 9 AM Peripheral iridotomy perform ≥ 1 Month prior Screening visit Anterior chamber angle trabecular meshwork visible ≥180 degree gonioscopy without indentation Peripheral anterior synechiae ( PAS ) Traumatic damage anterior chamber angle History ocular inflammation surgery ( except iridotomy ) ≤ 3 month Patients safely discontinue use ocular hypotensive medication ( ) 12 day 14 week Visual Acuity ≥ 1.0 Contact lens wearer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>IOP lower efficacy</keyword>
	<keyword>CACG</keyword>
</DOC>